Equities

NANO MRNA Co Ltd

NANO MRNA Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)195.00
  • Today's Change0.00 / 0.00%
  • Shares traded245.00k
  • 1 Year change-16.67%
  • Beta0.8007
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments4,2784,4445,945
Total Receivables, Net2936119
Total Inventory0.180.6533
Prepaid expenses----200
Other current assets, total1551896.66
Total current assets4,4624,6696,304
Property, plant & equipment, net006.53
Goodwill, net------
Intangibles, net00.150.15
Long term investments358886597
Note receivable - long term------
Other long term assets251229205
Total assets5,0715,7847,136
LIABILITIES
Accounts payable0.256.181.96
Accrued expenses----63
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total486358296
Total current liabilities487364361
Total long term debt1,1091,1091,150
Total debt1,1091,1091,150
Deferred income tax--9.498.23
Minority interest------
Other liabilities, total544850
Total liabilities1,6501,5311,569
SHAREHOLDERS EQUITY
Common stock142119348
Additional paid-in capital5,5235,5009,950
Retained earnings (accumulated deficit)(2136)(1369)(4687)
Treasury stock - common(0.03)(0.03)(0.03)
Unrealized gain (loss)(108)4.18(44)
Other equity, total00.000.00
Total equity3,4214,2535,567
Total liabilities & shareholders' equity5,0715,7847,136
Total common shares outstanding707070
Treasury shares - common primary issue0.010.010.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.